Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 389.21 Million EUR | 24.61% |
| 2022 | 312.33 Million EUR | -19.08% |
| 2021 | 385.96 Million EUR | 8.73% |
| 2020 | 354.98 Million EUR | -3.75% |
| 2019 | 368.82 Million EUR | 18.07% |
| 2018 | 312.37 Million EUR | 8.18% |
| 2017 | 288.76 Million EUR | 21.63% |
| 2016 | 237.4 Million EUR | 19.42% |
| 2015 | 198.79 Million EUR | 23.33% |
| 2014 | 161.18 Million EUR | 20.58% |
| 2013 | 133.67 Million EUR | 12.82% |
| 2012 | 118.48 Million EUR | 1.76% |
| 2011 | 116.43 Million EUR | 7.24% |
| 2010 | 108.57 Million EUR | -1.8% |
| 2009 | 110.56 Million EUR | 10.09% |
| 2008 | 100.42 Million EUR | 18.33% |
| 2007 | 84.86 Million EUR | 14.63% |
| 2006 | 74.03 Million EUR | 14.7% |
| 2005 | 64.54 Million EUR | 21.48% |
| 2004 | 53.13 Million EUR | 123.73% |
| 2003 | 23.74 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 123.59 Million EUR | 45.88% |
| 2024 Q2 | 101.77 Million EUR | -17.65% |
| 2023 Q4 | 84.72 Million EUR | 10.14% |
| 2023 Q2 | 103.61 Million EUR | -16.41% |
| 2023 Q1 | 123.95 Million EUR | 74.88% |
| 2023 Q3 | 76.92 Million EUR | -25.76% |
| 2023 FY | 389.21 Million EUR | 24.61% |
| 2022 Q3 | 90.05 Million EUR | 64.68% |
| 2022 FY | 312.33 Million EUR | -19.08% |
| 2022 Q1 | 96.72 Million EUR | 7.97% |
| 2022 Q2 | 54.68 Million EUR | -43.46% |
| 2022 Q4 | 70.87 Million EUR | -21.29% |
| 2021 Q1 | 89.87 Million EUR | 11.06% |
| 2021 Q4 | 89.58 Million EUR | 0.31% |
| 2021 Q3 | 89.3 Million EUR | -23.81% |
| 2021 FY | 385.96 Million EUR | 8.73% |
| 2021 Q2 | 117.21 Million EUR | 30.42% |
| 2020 Q4 | 80.92 Million EUR | 4.89% |
| 2020 FY | 354.98 Million EUR | -3.75% |
| 2020 Q1 | 111.18 Million EUR | -3.47% |
| 2020 Q2 | 85.73 Million EUR | -22.89% |
| 2020 Q3 | 77.14 Million EUR | -10.02% |
| 2019 Q3 | 79.39 Million EUR | -3.36% |
| 2019 FY | 368.82 Million EUR | 18.07% |
| 2019 Q4 | 115.18 Million EUR | 45.09% |
| 2019 Q1 | 92.1 Million EUR | 23.57% |
| 2019 Q2 | 82.15 Million EUR | -10.8% |
| 2018 FY | 312.37 Million EUR | 8.18% |
| 2018 Q4 | 74.53 Million EUR | 1.16% |
| 2018 Q3 | 73.67 Million EUR | -5.04% |
| 2018 Q2 | 77.58 Million EUR | -10.39% |
| 2018 Q1 | 86.58 Million EUR | 25.51% |
| 2017 Q1 | 78.5 Million EUR | 42.46% |
| 2017 Q2 | 68.46 Million EUR | -12.79% |
| 2017 Q3 | 72.81 Million EUR | 6.35% |
| 2017 FY | 288.76 Million EUR | 21.63% |
| 2017 Q4 | 68.98 Million EUR | -5.26% |
| 2016 Q4 | 55.1 Million EUR | -7.53% |
| 2016 Q1 | 65.47 Million EUR | 41.42% |
| 2016 Q2 | 57.23 Million EUR | -12.58% |
| 2016 Q3 | 59.59 Million EUR | 4.13% |
| 2016 FY | 237.4 Million EUR | 19.42% |
| 2015 Q4 | 46.29 Million EUR | -6.01% |
| 2015 Q1 | 51.96 Million EUR | 39.8% |
| 2015 Q2 | 51.27 Million EUR | -1.33% |
| 2015 Q3 | 49.25 Million EUR | -3.93% |
| 2015 FY | 198.79 Million EUR | 23.33% |
| 2014 FY | 161.18 Million EUR | 20.58% |
| 2014 Q2 | 40.27 Million EUR | -5.81% |
| 2014 Q4 | 37.17 Million EUR | -9.29% |
| 2014 Q3 | 40.97 Million EUR | 1.73% |
| 2014 Q1 | 42.76 Million EUR | 32.77% |
| 2013 Q4 | 32.2 Million EUR | 3.29% |
| 2013 Q2 | 32.52 Million EUR | -13.87% |
| 2013 Q1 | 37.76 Million EUR | 48.8% |
| 2013 FY | 133.67 Million EUR | 12.82% |
| 2013 Q3 | 31.18 Million EUR | -4.13% |
| 2012 Q1 | 33.77 Million EUR | 38.41% |
| 2012 Q2 | 29.48 Million EUR | -12.69% |
| 2012 Q3 | 29.85 Million EUR | 1.24% |
| 2012 Q4 | 25.37 Million EUR | -14.99% |
| 2012 FY | 118.48 Million EUR | 1.76% |
| 2011 Q4 | 24.4 Million EUR | -17.81% |
| 2011 FY | 116.43 Million EUR | 7.24% |
| 2011 Q1 | 31.42 Million EUR | 45.8% |
| 2011 Q2 | 30.92 Million EUR | -1.57% |
| 2011 Q3 | 29.68 Million EUR | -4.01% |
| 2010 Q4 | 21.55 Million EUR | -22.52% |
| 2010 Q2 | 29.23 Million EUR | -2.48% |
| 2010 FY | 108.57 Million EUR | -1.8% |
| 2010 Q3 | 27.81 Million EUR | -4.85% |
| 2010 Q1 | 29.97 Million EUR | 18.53% |
| 2009 FY | 110.56 Million EUR | 10.09% |
| 2009 Q1 | 27.61 Million EUR | 0.0% |
| 2009 Q2 | 30.12 Million EUR | 9.06% |
| 2009 Q4 | 25.28 Million EUR | -8.15% |
| 2009 Q3 | 27.53 Million EUR | -8.59% |
| 2008 FY | 100.42 Million EUR | 18.33% |
| 2007 FY | 84.86 Million EUR | 14.63% |
| 2006 FY | 74.03 Million EUR | 14.7% |
| 2005 FY | 64.54 Million EUR | 21.48% |
| 2004 FY | 53.13 Million EUR | 123.73% |
| 2003 FY | 23.74 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 93.464% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 95.15% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | 53.158% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 788.728% |
| Novartis AG | 14.85 Billion USD | 97.379% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -116.584% |